{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:48Z","timestamp":1753891848924,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["22YF7FA097 \u7f16\u53f7: 22YF7FA097"],"award-info":[{"award-number":["22YF7FA097 \u7f16\u53f7: 22YF7FA097"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2022-ZD-47;2022-5-51;2023-2-1022022-ZD-47;2022-5-51;2023-2-102"],"award-info":[{"award-number":["2022-ZD-47;2022-5-51;2023-2-1022022-ZD-47;2022-5-51;2023-2-102"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["GSWSHL2020-17"],"award-info":[{"award-number":["GSWSHL2020-17"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Human epidermal growth factor receptor 2 (HER2) is an anti-cancer drug target for colon cancer. Among patients with colorectal malignancy (colorectal cancer, CRC), those with HER2 mutations have a poor overall prognosis and a significantly increased drug resistance. In recent years, anti-HER2 therapeutic drugs have developed rapidly. According to several clinical studies and case reports, anti-HER2 therapy, as an emerging anti-cancer approach, plays a crucial role in the treatment of HER2-positive CRC patients. Here, we present a case of HER2-positive descending colon cancer with peritoneal metastasis. The patient is a 26-year-old male, diagnosed with malignant tumor of the descending colon with peritoneal metastasis in April 2020. After multiple treatment modalities, the disease progressed. After chemotherapy with Trastuzumab Deruxtecan (T-DXd\/DS-8201), the metastatic foci significantly shrank, and after surgical resection, a tumor-free state (NED) was achieved. Up to now, the patient\u2019s survival period has reached 56 months.<\/jats:p>","DOI":"10.3389\/fonc.2025.1473620","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T05:14:53Z","timestamp":1741929293000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of HER2-positive descending colon cancer with peritoneal metastasis and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yaochun","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengpeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/bjs5.50299","article-title":"Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study","volume":"4","author":"V\u00e4yrynen","year":"2020","journal-title":"BJS Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12052072","article-title":"Stage IV colorectal cancer management and treatment","volume":"12","author":"Hernandez Dominguez","year":"2023","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000873","article-title":"Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)","volume":"34","author":"Gaye","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.07.001","article-title":"ERBB2 (HER2) alterations in colorectal cancer","volume":"24","author":"Roy-Chowdhuri","year":"2022","journal-title":"J Mol Diagn"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e98528","DOI":"10.1371\/journal.pone.0098528","article-title":"HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression","volume":"9","author":"Seo","year":"2014","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-019-04441-4","article-title":"Peritoneal metastases in colorectal cancer: biology and barriers","volume":"24","author":"Xue","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3501","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing\/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study","volume":"41","author":"Raghav","year":"2023","journal-title":"J Clin Oncol"},{"key":"B12","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface Malignancy: expert consensus statements","volume":"22","author":"Yan","year":"2021","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i30.10852","article-title":"Hyperthermic intraperitoneal chemotherapy and colorectal cancer: From physiology to surgery","volume":"10","author":"Ammerata","year":"2022","journal-title":"World J Clin Cases"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.04.053","article-title":"A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with Raltitrexed","volume":"92","author":"Qiu","year":"2017","journal-title":"BioMed Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2017.03.001","article-title":"HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy","volume":"16","author":"Takegawa","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.676","article-title":"Pertuzumab + trastuzumab for HER2-amplified\/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway","volume":"35","author":"Hurwitz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/path.4679","article-title":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","volume":"238","author":"Richman","year":"2016","journal-title":"J Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8006","article-title":"Genomic markers of panitumumab resistance including ERBB2\/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)","volume":"7","author":"Barry","year":"2016","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-15-A145","article-title":"Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies","author":"Ogitani","year":"2015"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1531158","article-title":"Comprehensive Preclinical Pharmacokinetic Evaluations of Trastuzumab Deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in Cynomolgus Monkeys","author":"Nagai","year":"2018","journal-title":"Xenobiotica"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/fon-2021-0550","article-title":"Trastuzumab deruxtecan for HER2+ advanced breast cancer","volume":"18","author":"Lee","year":"2022","journal-title":"Future Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1890710","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond","volume":"21","author":"Perez","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1473620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T05:14:58Z","timestamp":1741929298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1473620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":27,"alternative-id":["10.3389\/fonc.2025.1473620"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1473620","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"article-number":"1473620"}}